Benzinga | Jun 4, 2021 10:05AM EDT

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

* Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former's SRF388, anti-IL-27 antibody, in combination with Roche's atezolizumab and bevacizumab in patients with treatment-na?ve hepatocellular carcinoma (HCC).

* Atezolizumab plus bevacizumab has been shown to improve overall survival significantly and is the new standard of care for unresectable or metastatic HCC.

* "This collaboration leverages Roche's deep experience in hepatocellular carcinoma and Surface's commitment to rationally and rapidly develop SRF388, a first-in-class antibody against IL-27, to provide a meaningful benefit to patients with liver cancer," said Surface Oncology chief medical officer Alison O'Neill.

* Price Action: SURF shares are down 1.68% at $8.91 during the market session on the last check Friday.